Furthermore, we find an accumulation and distribution of genomic alterations that deviates from other subgroups of NSCLC, such as an increased incidence of MET exon 14 skipping events and much less activating mutations in EGFR. The gene discussed is MET; the disease is non-small cell lung carcinoma.